Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Luye Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2022
Details:
This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.
Lead Product(s): Secnidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Solosec
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 27, 2022
Details:
Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizaport
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: IntelGenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 27, 2020